Sumitomo Pharma Co Ltd
TSE:4506

Watchlist Manager
Sumitomo Pharma Co Ltd Logo
Sumitomo Pharma Co Ltd
TSE:4506
Watchlist
Price: 568 JPY -0.53% Market Closed
Market Cap: 226B JPY
Have any thoughts about
Sumitomo Pharma Co Ltd?
Write Note

Sumitomo Pharma Co Ltd
Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Sumitomo Pharma Co Ltd
Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Sumitomo Pharma Co Ltd
TSE:4506
Cash Equivalents
ÂĄ99.1B
CAGR 3-Years
-14%
CAGR 5-Years
-10%
CAGR 10-Years
13%
Takeda Pharmaceutical Co Ltd
TSE:4502
Cash Equivalents
ÂĄ859B
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
2%
Daiichi Sankyo Co Ltd
TSE:4568
Cash Equivalents
ÂĄ707.7B
CAGR 3-Years
9%
CAGR 5-Years
19%
CAGR 10-Years
15%
Otsuka Holdings Co Ltd
TSE:4578
Cash Equivalents
ÂĄ515.1B
CAGR 3-Years
5%
CAGR 5-Years
6%
CAGR 10-Years
1%
Chugai Pharmaceutical Co Ltd
TSE:4519
Cash Equivalents
ÂĄ462.9B
CAGR 3-Years
34%
CAGR 5-Years
21%
CAGR 10-Years
16%
Astellas Pharma Inc
TSE:4503
Cash Equivalents
ÂĄ293B
CAGR 3-Years
-3%
CAGR 5-Years
-1%
CAGR 10-Years
-4%
No Stocks Found

Sumitomo Pharma Co Ltd
Glance View

Market Cap
225.7B JPY
Industry
Pharmaceuticals

In the bustling world of pharmaceuticals, Sumitomo Pharma Co. Ltd. stands as a testament to innovation and resilience. Emerging from its roots in Sumitomo Dainippon Pharma, this Japanese giant has been weaving a complex tapestry of cutting-edge medical advancements and strategic mergers for decades. At its core, Sumitomo Pharma is fueled by an unwavering commitment to research and development, driving its efforts in therapeutic areas such as psychiatry, neurology, and oncology. These focal points aren't mere business segments but vital lifelines that the company seeks to improve with its products. Their success heavily relies on their ability to translate research into actionable, marketable treatments; it's a dance between science and commerce, with the rhythm dictated by patient needs and market demands. Sumitomo Pharma's financial engine is powered not just by their innovative drug pipeline but also through savvy global partnerships and strategic acquisitions. By expanding its footprint across North America, Europe, and Asia, the company meticulously builds a global distribution network that ensures its products reach the hands of physicians and patients worldwide. This extensive reach allows Sumitomo Pharma to tap into diverse markets, fueling both sales and brand recognition. Moreover, through its alliances with biotech firms and academic institutions, the company enhances its research capabilities, fostering a cycle of innovation that feeds back into its financial growth. In essence, Sumitomo Pharma doesn't just participate in the pharmaceutical industry; it actively shapes it, both through its dedication to breakthrough therapies and its strategic navigation of complex global markets.

Intrinsic Value
776.5 JPY
Undervaluation 27%
Intrinsic Value
Price

See Also

What is Sumitomo Pharma Co Ltd's Cash Equivalents?
Cash Equivalents
99.1B JPY

Based on the financial report for Sep 30, 2024, Sumitomo Pharma Co Ltd's Cash Equivalents amounts to 99.1B JPY.

What is Sumitomo Pharma Co Ltd's Cash Equivalents growth rate?
Cash Equivalents CAGR 10Y
13%

Over the last year, the Cash Equivalents growth was 64%. The average annual Cash Equivalents growth rates for Sumitomo Pharma Co Ltd have been -14% over the past three years , -10% over the past five years , and 13% over the past ten years .

Back to Top